38
Iron deficient and megaloblastic anemias Atanas Stanchev MD University Hospital”Alexandrovska” Clinic of Hematology

Irion defitient and megaloblastic anemias

Embed Size (px)

Citation preview

Page 1: Irion defitient and megaloblastic anemias

Iron deficient and megaloblastic anemias

Atanas Stanchev MD

University Hospital”Alexandrovska”

Clinic of Hematology

Page 2: Irion defitient and megaloblastic anemias

Anemia

Page 3: Irion defitient and megaloblastic anemias

Red cells development

Page 4: Irion defitient and megaloblastic anemias

Normal red cellSize 7µмMCV 82-98flMCH 27-32pgMCHC 310-340g/l

Page 5: Irion defitient and megaloblastic anemias

Anemia is a symptom of disease that requires

investigation to determine the underlying aetiology.

Anemia is strictly defined as a decrease in red blood

cell (RBC) mass.

In practice, anemia is usually discovered and

quantified by measurement of the RBC count, hemoglobin

(Hb) concentration, and hematocrit (Hct)

Page 6: Irion defitient and megaloblastic anemias

Normal value

Parameter Men Women

Hb 140-180g/l 120-160g/l

Er. 4.6 – 6.6 T/l 4.2 – 5.4 T/l

Hct 40 – 54% 34 – 46%

Iron 12.5 – 26.5mol/l 10.7 - 23 mol/l

Ferritin 30 – 180 g/l 20 – 180 g/l

TIBC 40-75 mol/l 40-75 mol/l

Page 7: Irion defitient and megaloblastic anemias

Definition for anemia (WHO)

• Men Hb<130g/l

• Women Hb<120g/l

• Pregnant women Hb<100g/l

Classification

• Mild Hb90g/l

• Intermediate Hb.60-90g/l

• Severe Hb<60g/l

Page 8: Irion defitient and megaloblastic anemias

Iron deficiency anemia

Page 9: Irion defitient and megaloblastic anemias

•Iron deficiency is defined as a decreased total iron body content

•Iron deficiency anemia occurs when iron deficiency is sufficiently severe to diminish erythropoiesis and cause the development of anemia

•Iron deficiency is the most prevalent single deficiency state on a worldwide basis

•In healthy subjects, the body concentration of iron is regulated carefully by absorptive cells in the proximal small intestine

•Persistent errors in iron balance lead to either iron deficiency anemia or hemosiderosis

Page 10: Irion defitient and megaloblastic anemias

Dietary iron enters the enterocyte after being reduced to the ferrous state by duodenal cytochrome b (Dcytb) and being transported by the divalent metaltransporter (DMT1). Hephaestin facilitates iron export by ferroportin. Hepatocytes take up either free or transferrin-bound iron and release it back into the circulation via the action of ferroportin. Ferroportin also releases iron from macrophages. Ferroportin-mediated release of iron is inhibited by hepcidin.

Page 11: Irion defitient and megaloblastic anemias

Iron metabolism

Total amount of iron in adult male is 3.5-4.0g. (75% in Hb.; 10% in Myoglobine; 20% Iron stores (Ferritin; Hemostiderin)

• 10ml. whole blood contain 5mg. Iron

• Daily loss of Iron is 1mg.. Menstruating women loose additional 25-30mg. Iron for a month

•In normal daily food there is app. 12-15mg. Iron; 3.5mg. entering intestinal mucosa; 1-1.5mg. can be absorbed

• Only Fe++ (ferro) form can be absorbed; Absorption increase in presence of Ascorbic acid and diminish in presence of phosphates and oxalates

• Iron stores

•Ferritin (active)(N 50-150ug/l)

•Hemosiderin (inactive)

Page 12: Irion defitient and megaloblastic anemias

Causes for Iron deficiency• Increased demand for iron and/or hematopoiesis

• Rapid growth in infancy or adolescence

• Pregnancy

• Erythropoietin therapy

• Increased iron loss

• Chronic blood loss

• Menses

• Acute blood loss

• Blood donation

• Phlebotomy as treatment for polycythemia vera

• Decreased iron intake or absorption

• Inadequate diet

• Malabsorption from disease (sprue, Crohn's disease)

• Malabsorption from surgery (post-gastrectomy)

• Acute or chronic inflammation

Page 13: Irion defitient and megaloblastic anemias

Symptoms:

• Fatigue

• Tachycardia

• Pallor

• Koilonychia

• Glossitis

• Angular stomatitis

• Gastric atrophy.

• Head ache

Page 14: Irion defitient and megaloblastic anemias
Page 15: Irion defitient and megaloblastic anemias
Page 16: Irion defitient and megaloblastic anemias

Laboratory:• CBC with differential

•Red cells morphology (blood smear)

•Red cells indices (MCV; MCH; MCHC)

•Serum Iron; TIBC; Ferritin; TrSat (N 30-50%)

•Bone marrow aspirate with Perl’s staining (Iron stores)

•Testing stool for the presence of hemoglobin

•Gastroscopy

•Colonoscopy

• Gynecologist consultation

Page 17: Irion defitient and megaloblastic anemias
Page 18: Irion defitient and megaloblastic anemias
Page 19: Irion defitient and megaloblastic anemias

Treatment

• Establishing the diagnosis and reason for the iron deficiency

• The iron deficiency should be treated with oral iron therapy, and the underlying etiology should be corrected so the deficiency does not reocur.

• The most economical and effective medication in the treatment of iron deficiency anemia is the oral administration of ferrous iron salts (ferrous sulfate)

• Reserve parenteral iron for patients who are either unable to absorb oral iron or who have increasing anemia despite adequate doses of oral iron. It is expensive and has greater morbidity than oral preparations of iron.

Page 20: Irion defitient and megaloblastic anemias

Reticulocytosis on day 3-4 , max. on day 10

Page 21: Irion defitient and megaloblastic anemias

Drug Name

•Ferrous sulfate -Mainstay treatment for treating patients with iron deficiency anemia. They should be continued for about 2 mo after correction of the anemia and its etiological cause in order to replenish body stores of iron. Ferrous sulfate is the most common and cheapest form of iron utilized. Tablets contain 50-60 mg of iron salt. Other ferrous salts are used and may cause less

intestinal discomfort because they contain a smaller dose of iron (25-50 mg).

Contraindications

•Documented hypersensitivity; microcytic anemias without laboratory

documentation of iron deficiency

Interactions

•Calcium supplementation decreases bioavailability of iron when metals are ingested simultaneously; absorption is enhanced by ascorbic acid; interferes with tetracycline absorption; food and antacids impair absorption

Page 22: Irion defitient and megaloblastic anemias

Prognosis:

• Iron deficiency anemia is an easily treated disorder with an excellent outcome; however, it may be caused by an underlying condition with a poor prognosis, such as neoplasia. Similarly, the prognosis may be altered by a comorbid condition such as coronary artery disease.

Medical Pitfalls:

•Failure to investigate the etiology of the iron deficiency anemia causing a delayed or missed diagnosis of neoplasm•Anaphylaxis pursuant to the use of parenteral iron therapy in patients who should be treated with oral iron

Page 23: Irion defitient and megaloblastic anemias

Megaloblastic anemia

Page 24: Irion defitient and megaloblastic anemias

• Megaloblastic anemias are a heterogeneous group of disorders that share common morphologic characteristics

• The most common causes of megaloblastosis are cobalamin (vitamin B-12) and folate deficiencies (vitamin B9)

• Folate deficiency is usually due to folate-poor diets but may also occur in patients with sprue, during pregnancy, and in patients on antifolate or other medications

• The molecular basis for megaloblastosis is a failure in the synthesis and assembly of DNA

Page 25: Irion defitient and megaloblastic anemias

The assimilation of cobalamin. On entering the stomach, dietary cobalamin (Cbl) forms a complex with R binding protein. As this protein is digested in the small intestine, cobalamin is transferred to intrinsic factor (IF). This complex passes through the intestine until it reaches specific receptors on the mucosa of the distal ileum. The internalized Cbl is then transferred to transcobalamin II (TC II), which circulates in the plasma until it binds to receptors on cells throughout the body and is internalized.

Page 26: Irion defitient and megaloblastic anemias

Folate is essential for the de novo synthesis of purines, serving as an intermediate carrier of 1-carbon fragments used in the biosynthesis of these compounds. Its active form is tetrahydrofolate (THF)..

Page 27: Irion defitient and megaloblastic anemias

COBALAMIN DEFICIENCY

I. Inadequate intake: vegetarians (rare)

II. Malabsorption

A. Defective release of cobalamin from food: (Gastric achlorhydria; Partial gastrectomy; Drugs that block acid secretion)

B. Inadequate production of intrinsic factor (IF): ( Pernicious anemia; Total gastrectomy; Congenital absence or functional abnormality of IF (rare))

C. Disorders of terminal ileum: (Tropical sprue; Nontropical sprue; Regional enteritis; Intestinal resection; Neoplasms and granulomatous disorders (rare); Selective cobalamin malabsorption )

D. Competition for cobalamin: (Fish tapeworm (Diphyllobothrium latum); Bacteria: "blind loop" syndrome; Drugs: p-aminosalicylic acid, colchicine, neomycin)

III. Other

A. Nitrous oxide

B. Transcobalamin II deficiency (rare)

Page 28: Irion defitient and megaloblastic anemias

FOLIC ACID DEFICIENCYI. Inadequate intake: unbalanced diet (alcoholics, teenagers, some infants)II. Increased requirements

A. PregnancyB. InfancyC. MalignancyD. Increased hematopoiesis (chronic hemolytic anemias)E. Chronic exfoliative skin disordersF. Hemodialysis

III. MalabsorptionA. Tropical sprueB. Nontropical sprueC. Drugs: Phenytoin, barbiturates, ethanol

IV. Impaired metabolismA. Inhibitors of dihydrofolate reductase: methotrexate, triamterene,

pentamidine, trimethoprimB. AlcoholC. Rare enzyme deficiencies: dihydrofolate reductase, others

Page 29: Irion defitient and megaloblastic anemias

Clinical

1. Hematologycal symptoms: anemia; rare granulocyto or thrombocytopenia

2. Gastrointestinal symptoms: mucosal trophic changes; loss of appetite, weight loss, nausea, and constipation.

3. Neurological symptoms: paresthesias in the feet and fingers, poor gait, and memory loss. At later stages, patients can have severe disturbances in gait, loss of position sense, blindness due to optic atrophy, and psychiatric disturbances. In some patients, neurological impairment can occur without anemia. Therefore, neurological symptoms may range from mild to severe, and cobalamin deficiency should be considered even with minimal neurological symptoms and the absence of anemia.

Page 30: Irion defitient and megaloblastic anemias

Laboratory

1. Peripheral blood smear: hyperchromic megalocytes;

MCV>110fl.; MCH>34pg.; normal MCHC;

hypersegmented neutrophils; Low Reticulocyte count

2. Bone marrow: megaloblastic erythropoiresis: increased

erythroid/ myeloid ratio; Howell-Joly bodies(nuclear

fragments); giant myeloid precursors

3. Hight serum Iron level; High LDH and iBill level; Low

serum level of Cobalamin and Folic acid

Page 31: Irion defitient and megaloblastic anemias

Workup

1. Gastroscopy with biopsy

2. Schilling test

3. Neurologic status

4. anti IF Ab

Differential

1. MDS

2. Chemotherapy

3. Gastric cancer

4. Alcohol addiction

5. Bone marrow metastasis

Page 32: Irion defitient and megaloblastic anemias
Page 33: Irion defitient and megaloblastic anemias

This marrow section demonstrates so-called nuclear-cytoplasmic dissociation; The slow nuclear maturation is related to a decrease in DNA synthesis related to an insufficient supply of reduced folate to synthesize thymidylate. DNA synthesis inhibitors can produce this picture, as can folate and B12 deficiency.

Page 34: Irion defitient and megaloblastic anemias

Treatment

•Most patients with megaloblastosis are treated with cobalamin and folate therapy to treat deficiencies in these substances

•Transfusion therapy should be restricted to patients with severe, uncompensated, and life-threatening anemia

•Because megaloblastic anemias usually develop gradually, most patients have adjusted to low Hb levels and do not require transfusions.

•Cobalamin (1000 mcg) should be given parenterally daily for 2 weeks, then weekly until the hematocrit value is normal, and then monthly for life. This dose is large, but it may be required in some patients

•Folate should be administered orally (150-400 (400-800)g/d)

Page 35: Irion defitient and megaloblastic anemias

Prevention:

•Patients who have undergone either total or partial gastrectomies should receive lifelong monthly doses of cobalamin (1000 mcg IM).

Prognosis:

•Prognosis is good if the etiology of megaloblastosis is identified and appropriate treatment is instituted. However, patients are at risk for complications of anemia, such as cardiac impairment and hypokalemia, during therapy for cobalamin deficiency.

Page 36: Irion defitient and megaloblastic anemias

Medical Pitfalls:

•Failure to avoid treating patients with potential cobalamin deficiency with folate alone because this may lead to severe neuropsychiatric disease

•Failure to recognize and treat incipient neuropsychiatric impairment

•Failure to administer folate during pregnancies to avoid abnormal fetal development

•Failure to appropriately investigate macrocytosis

Page 37: Irion defitient and megaloblastic anemias

Bone marrow aspirate in megaloblastic anaemia showing early, intermediate and late megaloblasts and a giant metamyelocyte [arrow].

Page 38: Irion defitient and megaloblastic anemias

Bibliography:

• P. Apostolov, Internal medicine , 2004

•Harrison’s Principles of Internal medicine, 15th Edition

•B. Bain, Hematology image bank

•Marcel E Conrad, MD, Anemia, eMedicine 2004

•Marcel E Conrad, MD , Iron deficiency anemia, eMedicine 2004

•Paul Schick, MD, Megaloblastic anemia, eMedicine 2002